COVID-19 та постковідний синдром у фокусі ускладнень: рекомендації для лікарів

COVID-19: вияви з боку шлунково-кишкового тракту. Постковідний синдром при захворюваннях печінки

Автор(и)

  • О. Є. Гріднєв ДУ «Національний інститут терапії імені Л. Т. Малої НАМН України», Харків, Україна
  • Г. Д. Фадєєнко ДУ «Національний інститут терапії імені Л. Т. Малої НАМН України», Харків, Україна

DOI:

https://doi.org/10.30978/MG-2022-1-20

Анотація

-

Біографії авторів

О. Є. Гріднєв, ДУ «Національний інститут терапії імені Л. Т. Малої НАМН України», Харків

д. мед. н., ст. наук. співр., пров. наук. співр. відділу вивчення захворювань органів травлення і їх коморбідності з неінфекційними захворюваннями

Г. Д. Фадєєнко, ДУ «Національний інститут терапії імені Л. Т. Малої НАМН України», Харків

чл.-кор. НАМН України, д. мед. н., проф.,
директор Національного інституту терапії ім. Л. Т. Малої НАМН України,
зав. відділу вивчення захворювань органів травлення і їхньої коморбідності з неінфекційними захворюваннями

Посилання

Brenner E. J., Ungaro R. C., Gearry R. B. et al. Corticosteroids, but not TNF antagonists, are associated with adverse ­COVID‑19 outcomes in patients with inflammatory bowel diseases: results from an International Registry // Gastroenterology. — 2020. — 159. — P. 481 — 491. e3.

British Society of Gastroenterology expanded consensus advice for the management of IBD during the ­COVID‑19 pandemic. URL: https://www.bsg.org.uk/covid-19-advice/bsg-advice-for-management-of-inflammatory-bowel-diseases-during-the-covid-19-pandemic.

Burgueño J. F., Reich A., Hazime H. et al. Expression of SARS‑CoV‑2 entry molecules ACE2 and TMPRSS2 in the gut of patients with IBD // Inflamm. Bowel Dis. — 2020. — 26. — P. 797.

Chen L., Lou J., Bai Y. et al. ­COVID‑19 Disease with positive fecal and negative pharyngeal and sputum viral tests // The American Journal of Gastroenterology: March 20, 2020. — Volume Publish Ahead of Print.

Chen Y., Liu Q., Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis // J. Med Virol. — 2020. — 92 (4). — P. 418 — 23.

Cheung K. S., Ivan F. N., Hung M. D. et al. Gastrointestinal manifestations of SARS‑CoV‑2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis // Gastroenterology. — 2020. — 159 (1). — P. 81 — 95.

Di Renzo L., Merra G., Esposito E., De Lorenzo A. Are probiotics effective adjuvant therapeutic choice in patients with ­COVID‑19? // Eur. Rev. Med. Pharmacol. Sci. — 2020. — 24 (8). — P. 4062 — 3.

Fang D., Ma J.-D., Guan J.-L. et al. A single-center, descriptive study on the digestive system of ­COVID‑19 in patients in wuhan. Chinese J. Digest. — 2020. — 40. — E005–E005.

Gadiparthi C., Perisetti A., Sayana H. et al. Gastrointestinal bleeding in patients with severe SARS‑CoV‑2. Am. J. Gastroenterol. 2020 Aug;115 (8). — P. 1283 — 5.

Gao Q. Y., Chen Y. X., Fang J. Y. 2019 Novel coronavirus infection and gastrointestinal tract // J. Dig. Dis. — 2020. — 21 (3). — P. 125 — 6.

Garg M., Burrell L. M., Velkoska E. et al. Up regulation of circulating components of the alternative renin-angiotensin system in inflammatory bowel disease: a pilot study. J. Renin Angiotensin Aldosterone Syst. 2015. — 16. — P. 559 — 69.

Grinevich V. B., Kravchuk, A.Yu., Tkachenko E. I. et al. Features of management of patients with gastroenterological pathology in the conditions of the ­COVID‑19 pandemic // Exp. Clin. Gastroenterol. — 2020. — 176 (4).

Gralnek I. M., Hassan C., Beilenhoff U. et al. ESGE and ESG NA Position Statement on gastrointestinal endoscopy and the ­COVID‑19 pandemic. Endoscopy. — 2020. — 52 (6). — P. 483 — 90.

Groves H. T., Higham S. L., Moffatt M. F., Cox M.J, Tregoning J. S. Respiratory viral infection alters the gut microbiota by inducing in appetence. MBio. 2020 Feb;11 (1):e03236 — 19.

Gu J., Han B., Wang J. ­COVID‑19: Gastrointestinal manifestations and potential fecal-oral transmission // Gastroenterology. — 2020. doi.org/10.1053/j.gastro.2020.02.054.

Gu S., Chen Y., Wu Z. et al. Alterations of the gut microbiota in patients with ­COVID‑19 or H1N1 influenza // Clin. Infect. Dis. 2020 Jun;ciaa709. Epub.

Han C., Duan C., Zhang S. et al. Digestive symptoms in ­COVID‑19 patients with mild disease severity: clinical presentation, stool viral RNA testing, and outcomes. Am. J. Gastroenterol. 2020 Jun;115 (6). — P. 916 — 23.

Hashimoto T., Perlot T., Rehman A. et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature. — 2012. — 487 (7408). — P. 477 — 481.

Hoffmann M., Kleine-Weber H., Schroeder S. et al. SARS‑CoV‑2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. — 2020. 10.1016/j.cell.2020.02.052.

Jin X., Lian J.-S., Hu J.-H. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (­COVID‑19) with gastrointestinal symptoms // Gut. — 2020 gutjnl-2020 — 320926.

Kennedy N. A., Jones G. R., Lamb C. A. et al. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the ­COVID‑19 pandemic // Gut. — 2020. — 69 (6). — P. 984 — 90.

Khan N., Patel D., Xie D. et al. Impact of anti-TNF and thiopurines medications on the development of ­COVID‑19 in patients with inflammatory bowel disease: a nationwide VA cohort study. Gastroenterology. Epub ahead of print 29 May 2020. doi: 10.1053/j.gastro.2020.05.065.

Lees C. W., Regueiro M., Mahadevan U. International Organization for the Study of Inflammatory Bowel Disease. Innovation in IBD care during the ­COVID‑19 pandemic: results of a global telemedicine survey by the international organization for the study of inflammatory bowel disease. Gastroenterology. Epub ahead of print 28 May 2020. doi: 10.1053/j.gastro.2020.05.063.

Lei P., Mi M., Pengcheng Y. et al., Clinical characteristics of ­COVID‑19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study // Am. J. Gastroenterol./ journals.lww.com/ajg/Documents/ COVID_Digestive_Symptoms_AJG_Preproof.pdf.

Li F., Lu H., Li X. et al. The impact of ­COVID‑19 on intestinal flora A protocol for systematic review and meta analysis Medicine (Baltimore). 2020 Sep 25. — 99 (39): e22273. Published online. 2020 Sep. 25. doi: 10.1097/MD.0000000000022273.

Ma C., Cong Y., Zhang H. ­COVID‑19 and the Digestive System // Am. J. Gastroenterol. — 2020. — 00. — P. 1 — 4. doi: 10.14309/ajg.0000000000000691.

Mao R., Qiu Y., He J. S., Tan J. Y., Li X. H., Liang J. et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with ­COVID‑19: a systematic review and meta-analysis // Lancet. Gastroenterol. Hepatol. — 2020. — 5 (7). — P. 667 — 678. doi: 10.1016/S2468-1253 (20)30126-6.

Monteleone G., Ardizzone S. Are patients with inflammatory bowel disease at increased risk for Covid-19 infection? // J. Crohn’s Colitis. — 2020. — 14 (9). — P. 1334 — 6.

Morrow L. E., Kollef M. H., Casale T. B. Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am. J. Respir. Crit. Care Med. — 2010. — 182 (8). — P. 1058 — 64.

Naito Y., Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev. Gastroenterol. Hepatol. — 2010. — 4 (3). — P. 261 — 70. doi: 10.1586/egh.10.25.38-4.

Nakase H., Matsumoto T., Matsuura M. et al. Expert opinions on the current therapeutic management of inflammatory bowel disease during the ­COVID‑19 pandemic: Japan IBD ­COVID‑19 Taskforce, Intractable Diseases, the Health and Labor Sciences Research.

Nobel Y. R., Phipps M., Zucker J. et al. Gastrointestinal symptoms and coronavirus disease 2019: A case-control study from the United States // Gastroenterology. — 2020. — 159. — P. 373 — 375.e2.

Novak J. K. et al. Age, inflammation and disease location are critical determinants of intestinal expression of SARS‑CoV‑2 receptor ACE2 and TMPRSS2 in inflammatory bowel disease // Gastroenterology. — 2020. — 12:S0016 — 5085 (20)30653 — 3.

Pan L., Mu M., Ren H. G. Clinical characteristics of ­COVID‑19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Practice Update. https://www.practiceupdate.com/content/clinical-characteristics-of-covid-19-patients-with-digestive-symptoms-in-hubei-china/98000.

Papa A., Papa V., Lopetuso L. R. et al. Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase // Therap. Adv. Gastroenterol. — 2020. — 13: Published online 2020 Oct 24. doi: 10.1177/1756284820968747.

Parasa S., Desai M., Thoguluva Chandrasekar V. et al. Prevalence of gastrointestinal symptoms and fecal viral shedding in patients with coronavirus disease 2019: A systematic review and meta-analysis // JAMA. Netw. Open. — 2020 Jun;3 (6). — e201133.

Redd W. D., Zhou J. C., Hathorn K. E. et al. Prevalence and characteristics of gastrointestinal symptoms in patients with severe acute respiratory syndrome coronavirus 2 infection in the United States: A multicenter cohort study // Gastroenterology. — 2020. — 159. — P. 765.

Rubin D. T., Abreu M. T., Rai V.;On behalf of the International Organization for the STUDY OF INFLAMMATORY BOWEL DISEASE. Management of Patients with Crohn’s Disease and Ulcerative Colitis During the ­COVID‑19 Pandemic: Results of an International Meeting // Gastroenterology. — 2020. — doi:10.1053/j.gastro.2020.04.002.

Luo S., Zhang X., Xu H. Don’t Overlook digestive symptoms in patients with 2019 novel coronavirus disease (­COVID‑19) // Clin. Gastroenterol. Hepatol. — 2020. — 18 (7). — P. 1636 — 1637. doi: 10.1016/j.cgh.2020.03.043.

Song Y., Liu P., Shi X. L. et al. SARS‑CoV‑2 induced diarrhea as onset symptom in patient with ­COVID‑19 // Gut. — 2020. — 69. — P. 1143 — 1144.

Sterne J. A. C., Murthy S., Diaz J. V. et al.; WHO Rapid Evidence Appraisal for ­COVID‑19 Therapies (REACT) Working Group/ Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With ­COVID‑19: A Meta-analysis // JAMA. — 2020. — 324. — P. 1 — 13.

Sultan S., Altayar O., Siddique S. M. et al. AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of ­COVID‑19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with ­COVID‑19 // Gastroenterology. — 2020. — 159. — P. 32.

Suresh Kumar V. C., Mukherjee S., Harne P. S. et al. Novelty in the gut: a systematic review and meta-analysis of the gastrointestinal manifestations of ­COVID‑19 // BMJ. — Open Gastroenterol. 2020 May;7 (1):e000417.

Tian Y., Rong L., Nian W., He Y. Review article: gastrointestinal features in ­COVID‑19 and the possibility of fecal transmission. Aliment. Pharmacol. Ther. 2020 May;51 (9). — P. 843 — 51.

Vuille-dit-Bille R. N., Camargo S. M., Emmenegger L. et al. Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors // Amino Acids. — 2015. — 47 (4). — P. 693 — 705.

Wang C., Pan R., Wan X. et al. Immediate psychological responses and associated factors during the initial stage of the 2019 coronavirus disease (­COVID‑19) epidemic among the general population in China // Int. J. Environ. Res. Public. Health. — 2020. — 17 (5). — P. 1729.

Wu Y., Guo C., Tang L. et al. Prolonged presence of SARS‑CoV‑2 viral RNA in faecal samples // Lancet. Gastroenterol. Hepatol. — 2020. — 5. — P. 434 — 435.

Xiao F., Tang M., Zheng X. et al. Evidence for gastrointestinal infection of SARS‑CoV‑2 // Gastroenterology. — 2020. — 158. — 1831 — 1833. e1833.

Young B. E., Ong S. W. X., Kalimuddin S. Epidemiologic features and clinical course of patients infected with SArS- CoV-2 in Singapore // JAMA. — 2020 doi: 10.1001/jama.2020.3204.

Yeoh Y. K., Zuo T., Chung-Yan G. L. et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with ­COVID‑19 // Gut. — 2021. — 0. — P. 1 — 9. doi: 10.1136/gutjnl-2020-323020.

Zuo T., Zhang F., Lui G. C. et al. Alterations in gut microbiota of patients with covid-19 during time of hospitalization // Gastroenterology. — 2020. — 159 (3). — P. 944 — 955. e8.

Lee I. C., Huo T. I., Huang Y. H. Gastrointestinal and liver manifestations in patients with ­COVID‑19 // J. Chin. Med. Assoc. — 2020. doi: 10.1097/JCMA.0000000000000319.

Greenhalgh T., Knight M., A’Court C., Buxton M., Husain L. Management of post-acute covid-19 in primary care // BMJ. — 2020. — Vol. 370. — m3026. doi: 10.1136/bmj.m30260319.

Geddes L. Why strange and debilitating coronavirus symptoms can last for months. New Scientist 2020.https://www.newscientist.com/article/mg24632881-400-why-strange-and-debilitating-coronavirus-symptoms-can-last-for-months/.

Sheehy L. M. Considerations for postacute rehabilitation for survivors of ­COVID‑19 // JMIR Public Health Surveill. — 2020. — Vol. 6. — e19462. doi: 10.2196/19462 pmid:32369030.

Corona Resource Centre [Electronic resource]. URL: https://coronavirus.jhu.edu/map.html (date of the application: 15.04.2021)

Téllez L., Martín Mateos RM. ­COVID‑19 and liver disease: An update // Gastroenterol. Hepatol. — 2020. — Vol. 43 (8). — P. 472 — 480. doi: 10.1016/j.gastrohep.2020.06.006.

##submission.downloads##

Опубліковано

2022-06-27

Номер

Розділ

Стандарти діагностики та лікування